Hafnia is a genus of gram-negative bacteria that is classified within the Enterobacteriaceae family. First identified in 1958, Hafnia alvei, the most notable species of this genus, is commonly found in various environments, including water, soil, and the intestines of animals. This microorganism has garnered attention in recent years due to its role as a potential biomarker in clinical diagnostics. Research has revealed that changes in Hafnia levels can be indicative of certain health conditions, particularly those related to the gastrointestinal system. Its presence may reflect shifts in the gut microbiome and overall metabolic processes, offering insights into health status and disease risk. As studies continue to explore its clinical relevance, Hafnia is emerging as a significant player in microbiome research and personalized medicine.

Elevated Hafnia levels may suggest an inflammatory response or an increased presence of pathogenic bacteria in the gut, which can be associated with gastrointestinal disturbances or infections. Conversely, low levels of Hafnia might indicate a lack of diversity in gut microbiota or potential imbalances in the microbial ecosystem, possibly leading to impaired gut health and associated metabolic or inflammatory conditions. It is essential to consider these levels in conjunction with other biomarkers and individual health factors for a comprehensive understanding.

Hafnia alvei is featured in the Gut Zoomer panel, which provides a comprehensive analysis of gut microbial diversity by evaluating various bacteria, inflammatory markers, and digestive metabolites. This distinctive biomarker plays a crucial role in gut health, as it has been associated with the breakdown of complex carbohydrates, nutrient absorption, and modulation of the immune response. By identifying Hafnia alvei levels, practitioners can better understand gut ecology and tailor interventions aimed at restoring balance and promoting overall wellness.